Adoptive T-cell transfer of in vitro cultured T cells derived from cancer patients with naturally developed immune responses has met with some success as an immunotherapeutic approach, although only a limited number of patients showed spontaneous immune responses. To find alternative ways, such as cancer-specific T-cell receptor (TCR) gene transfer, in preparation for sufficient numbers of antigenspecific T cells is an important issue in the field of adoptive T-cell therapy. Given the inherent disadvantage of ab TCR transfer to other ab T cells, namely the possible formation of mixed TCR heterodimers with endogenous a or b TCR, we employed gd T cells as a target for retroviral transfer of cancer-specific TCR and examined whether gd T cells were useful as an alternative population for TCR transfer. Although retroviral transduction to gd T cells with TCR ab genes alone, isolated from a MAGE-A4 143-151 -specific ab CD8 + cytotoxic T lymphocyte (CTL) clone, did not provide sufficient affinity to recognize major histocompatibility (MHC)-peptide complexes due to the lack of CD8 co-receptor, gd T cells co-transduced with TCR ab and CD8 ab genes acquired cytotoxicity against tumor cells and produced cytokines in both ab-and gd-TCR-dependent manners. Furthermore, ab TCR and CD8-transduced gd T cells, stimulated either through ab TCR or gd TCR, rapidly responded to target cells compared with conventional ab T cells, reminiscent of gd T cells. We propose ab TCRtransduced gd T cells as an alternative strategy for adoptive T-cell transfer.
Introduction
Adoptive T-cell transfer for treatment of cancer patients with spontaneously developed immune responses has been somewhat successful as an approach for immunotherapy. 1, 2 However, only a limited number of patients developed spontaneous immune responses, thus hampering exploitation of this therapeutic approach for a wider range of populations of cancer patients. 2, 3 Genetic modification of ab T cells from peripheral blood lymphocytes with T-cell receptor (TCR) genes cloned from tumor antigen-specific T cells has been introduced as an alternative strategy with potential therapeutic benefits. 2, 3 However, one of the inherent disadvantages of ab TCR transfer to other ab T cells is the possible formation of mixed TCR heterodimers, namely the introduced a or b TCR could pair with the endogenous a or b TCR chains to generate unfavorable T cells with self-antigen specificity. 2, 4 gd T cells have several important features, some of which are distinct from conventional ab T cells. 5, 6 The gd T cells rapidly expand upon antigen challenge. [7] [8] [9] gd T-cell deficiency is consistently deleterious to tumor resistance in mouse tumorigenesis models. 8 gd T cells recognize tumor cells independent of major histocompatibility (MHC) class I expression through non-peptide antigens, suggesting that gd T cells can recognize tumor cells even in the presence of impaired expression of MHC class I. 6, 10, 11 Recent studies have reported that aminobisphosphonates, currently used in cancer treatment for bone metastases, can activate gd T cells both in vitro and in vivo. 12, 13 These data prompted us to analyze whether gd T cells could be an alternative population for efficient TCR transfer. It has recently been shown that gd T cells transduced with ab TCR could recognize target cells in an ab TCR-dependent manner. 4, 14 However, the potential loss/enhancement of the original gd TCR signals by competition of TCR machineries with the transduced ab TCR, and the kinetics of activation through the transduced ab TCR and the original gd TCR were not determined.
MAGE-A4 is a germ cell protein often expressed by cancer cells, but not by normal somatic cells. 15, 16 We have reported a novel MAGE-A4 epitope bound to HLA-A*2402 and generated a CD8 + T cell clone that recognizes this epitope, and thereby identified the ab TCR from this clone. 17, 18 In this study, we examined whether gd T cells transduced with the ab TCR and CD8 ab genes by retroviral transfer were cytotoxic against MAGE-A4-expressing tumor cells and could produce cytokines in both ab-and gd-TCR-dependent manners. Furthermore, we also investigated the activation kinetics of TCR ab gene-transduced gd T cells in response to ligands for ab and gd TCRs.
Results
Co-transfer of CD8 is necessary to generate MAGE-A4 143-151 -specific gd T cells from PBMCs
The proportion of gd T cells in peripheral blood mononuclear cells (PBMCs) ranges from 2 to 5% in healthy individuals. To obtain a sufficient number of gd T cells, we activated gd T cells with 2-methyl-3-butenyl-1-pyrophosphate (2M3B1PP), a gd TCR ligand we have reported earlier 6, 13 and then transduced them with TCR ab genes isolated from a MAGE-A4 143-151 -specific ab CD8 + cytotoxic T lymphocytes (CTL) clone by retroviral transfer as described in Materials and Methods. After 2 weeks, the proportion of gd T cells increased to 75-98%. 6, 13 gd T cells transduced with MAGE-A4 143-151 -specific ab TCR alone did not bind to MAGE-A4 143-151 / HLA-A*2402 tetramers ( Figure 1 , TCR alone), suggesting that ab TCR identified from a CD8 + T cell clone that recognizes a MAGE-A4 epitope bound to HLA-A*2402 may be CD8 dependent. To address this, a retroviral vector for CD8 a and b genes was constructed ( Figure 2b ) and transduced into gd T cells with MAGE-A4 143-151 -specific ab TCR. As shown in Figures 1 and 3a , 20-42% of the expanded gd T cells transduced with both TCR ab and CD8 ab genes bound to MAGE-A4 143-151 /HLA-A*2402 tetramers. There is a gap among the percentage of Vg9+anti-CD8, Vg9+anti-abTCR and Vg9+HLA-A*2402/MAGE-A4 143-151 tetramer (Figure 1, TCR-CD8 ). This gap may be dependent on activity of each antibody, namely the activity of phycoerythrin (PE)-conjugated anti-CD8 and anti-ab TCR antibodies are weaker than of HLA-A*2402/MAGE-A4 143-151 tetramer. Alternatively, it is possible that ab TCR and CD8 synergistically enhance TCR affinity. CD8 expression lower than the level detected by anti-CD8 antibody may augment TCR affinity and bind to tetramers.
MAGE-A4 143-151 -specific CD8
+ gd T cells recognize target cells through the transduced ab TCR We then examined the capacity of these ab TCR and CD8 co-transduced gd T cells to recognize targets through the transduced ab TCR. Cells (Figure 3b ). The number of interferon (IFN)-g producing cells in ab TCR and CD8 co-transduced gd T cells was significantly higher compared with the clone 2-28. Next, the specific cytotoxicity through the transduced ab TCR was examined using human tumor cell lines 11-18 and SK-MEL-128 with MAGE-A4 and HLA-A*2402 expression. ab TCR and CD8 co-transduced gd T cells exclusively killed tumor cell lines expressing both MAGE-A4 and HLA-A*2402, but not those lacking the expression of HLA-A*2402 (Figure 4a ). The lytic activity of the transduced cells was inhibited by the addition of anti-CD8 or anti-MHC class I antibodies (Figures 4b and c) . Taken together, gd T cells transduced with both MAGE-A4 143-151 -specific ab TCR and CD8 recognize target cells in an ab TCR-dependent manner.
MAGE-A4 143-151 -specific CD8 + gd T cells are stimulated through both ab and gd TCRs
To avoid possible contamination of ab T cells, gd T cells co-transduced with both MAGE-A4 143-151 -specific TCR ab and CD8 ab genes were purified on a FACSAria (BD Biosciences, Franklin Lakes, NJ, USA) and the purity of the sorted cells was confirmed to be more than 99.5% ( Figure 5 ). The purified gd T cells transduced with both MAGE-A4 143-151 -specific TCR ab and CD8 ab genes, or control ab T cells transduced with MAGE-A4 143-151 -specific TCR ab genes, were stimulated with SKOV3-A*2402 pulsed with MAGE-A4 143-151 or control HER2 63-71 peptide, followed by analyses of cytokine production. As expected, both gd T cells and ab T cells transduced with MAGE-A4 143-151 -specific TCR ab genes recognized SKOV3-A*2402 pulsed with MAGE-A4 143-151 peptide, but not control peptide (Figure 6a ). In addition, gd T cells, but not ab T cells transduced with MAGE-A4 143-151 -specific TCR ab genes, were stimulated with pamidronate disodium-pretreated SKOV3-A*2402 (Figure 6a ). TCR ab and CD8 ab genes-transduced gd T cells secreted large amounts of IFN-g, but almost negligible amounts of interleukin 4 (IL-4) (Figure 6a ). SKOV3-A*2402 were pulsed with either MAGE-A4 143-151 peptide or control peptide, or treated with pamidronate disodium and the specific cytotoxicity of MAGE-A4 143-151 -specific CD8 + gd T cells was analyzed with 51 Cr release assays. MAGE-A4 143-151 -specific CD8 + gd T cells killed SKOV3-A*2402 pulsed with MAGE-A4 143-151 and also SKOV3-A*2402 pretreated with pamidronate disodium (Figure 6b ). In contrast, ab T cells transduced with MAGE-A4 143-151 -specific TCR ab genes showed lytic activity against SKOV3-A*2402 pulsed with MAGE-A4 143-151 , but not those pretreated with pamidronate disodium (Figure 6b ). Taken together, these results indicate that MAGE-A4 143-151 -specific CD8
+ gd T cells can recognize target cells through both ab and gd TCRs.
+ gd T cells are rapidly stimulated through both ab and gd TCR Considering that gd T cells are spontaneously activated and rapidly proliferate upon antigen challenge, we next examined the activation kinetics of MAGE-A4 143-151 -specific CD8
+ gd T cells after stimulation with ligands for ab and gd TCRs. MAGE-A4 143-151 -specific CD8 + gd T cells were stimulated with SKOV3-A*2402 cells treated with 2M3B1PP or pamidronate, in similar kinetics with gd T cells without ab TCR and CD8 ab retroviral transduction ( Figure 6c ). As expected, these gd T cells responded more rapidly to SKOV3-A*2402 treated by 2M3BIPP than those pretreated with pamidronates, reflecting the differing effects of these two molecules to gd T cells, namely direct or indirect recognition ( Figure  6c ). 6, 13, 19 Surprisingly, MAGE-A4 143-151 -specific CD8 + gd T cells responded to SKOV3-A*2402 pulsed with MAGE-A4 143-151 peptide through ab TCR, apparently more rapidly than TCR gene-transduced ab T cells, with kinetics reminiscent of stimulation with 2M3BIPP-treated SKOV3-A*2402 (Figure 6c) . A similar kinetics profile was also observed in the production of IFN-g (data not shown).
Discussion
Using Va and Vb TCR usage information of a MAGE-A4 143-151 -specific ab CD8 + CTL clone, we generated MSbPa, a retroviral vector harboring the a-and b-chain cDNAs, and this retroviral vector efficiently transduced TCR ab genes into ab T cells. 17, 18 These TCR ab genemodified T cells recognized not only MAGE-A4 143-151 peptide-pulsed T2-A*2402 but also tumor cell lines expressing MAGE-A4 and HLA-A*2402. 18 Using this promising retroviral vector, we found that: (1) the ab TCR was able to be transduced to gd T cells. Interestingly, gd TCR was downregulated after transduction of the ab TCR. One plausible explanation is that CD3 is essential for both ab and gd TCR expression on the T cells. As the amount of CD3 molecules is limited, usage of CD3 might be competed between ab and gd TCRs for the formation of TCR-CD3 complex and gd TCR was decreased after transduction of ab TCR. (2) Transduction with not only ab TCR but CD8 was necessary to render gd T cells responsive to MAGE-A4-expressing tumor cells, (3) MAGE-A4 143-151 -specific CD8
+ gd T cells were stimulated 
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A Hiasa et al in both ab-and gd-TCR-dependent manners and (4) TCR ab gene-transduced CD8 + gd T cells responding to ligands for ab and gd TCRs exhibited similar stimulation kinetics to gd T cells stimulated with a direct stimulant, 2M3BIPP. The rapid cytokine secretion after stimulation with ab and gd TCRs in gd T cells suggests that the transduced ab TCR signal shares the signal cascade with gd TCR signal.
Although ab TCR transduced ab T cells showed the similar killing activity against the target cells as ab TCR transduced gd T cells, the level of granzyme B in ab T cells is lower compared with those in gd T cells ( Figure 6 ). It is possible that gd T cells may have strong killing activity compared with ab T cells in lower effector/target ratio though we could not see the differences at the ratio tested. These data further support the advantage for using gd T cells as the target of TCR transduction.
It has been reported that antigen-specific T cells elicited by peptide vaccination can neither recognize naturally processed antigens nor kill tumor cells in a cancer/testis antigen NY-ESO-1 system as the TCR affinity of NY-ESO-1 peptide vaccine-induced T cells is relatively low compared with spontaneously-induced NY-ESO-1-specific T cells. 20, 21 The MAGE-A4 143-151 -specific CD8 + CTL clone used in this study shows high affinity against MAGE-A4 143-151 and recognizes naturally processed MAGE-A4 antigen. 17 However, whereas gd T cells transduced with TCR ab genes alone did not recognize MHC class I-peptide complexes, gd T cells transduced with MAGE-A4 143-151 -specific ab TCR responded promptly through ab TCR signals after co-transduction with CD8 ab genes, indicating the importance of CD8 signals for adoptive T cell transfer therapy employing gd T cells as a target of retroviral tumor antigen-specific TCR transfer. This finding is in line with the recent studies showing that ab TCR derived from both CD8 + and CD4 + T cell clones could be transduced into gd T cells and these ab TCR engineered gd T cells responded to target cells through the transduced ab TCR. 4, 14 It has been shown recently that the loss of colocalization of the TCR and CD8 is associated with a decrease in their effector activity and in their binding to MHC-peptide tetramers, and that TCR is observed to be distant from CD8 on human tumor-infiltrating lymphocytes which were anergic. 22 Our maneuver to cotransduce TCR ab and CD8 ab genes may provide an essential hint to resolve this problem. When considering adoptive T-cell therapy, the transferred T cells transduced with ab TCR infiltrate the tumor and are exposed to the pressure of tumors. gd T cells co-transduced with ab TCR and CD8 containing the saturated amounts of Peripheral blood mononuclear cells (PBMCs) were prepared from healthy donors. gd T cells were activated with 2-methyl-3-butenyl-1-pyrophosphate (2M3B1PP) and transduced with both MAGE-A4 143-151 -specific ab TCR and CD8. Cells transduced with both MAGE-A4 143-151 -specific ab TCR and CD8 co-receptor were stained with anti-Vg9 monoclonal antibody and MAGE-A4 143-151 /HLA-A*2402 tetramers and were purified on a FACSAria. The purity of sorted cells was more than 99.5%. HD3 and HD4 represent healthy donors 3 and 4, respectively. ab TCR transduced ab T cells were prepared as described earlier 18 and used as control after sorting on FACSAria.
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transduced with MAGE-A4 143-151 -specific ab TCR and CD8 co-receptor apparently maintained most of the features of gd T cells examined. The migration properties of human peripheral blood Vg9Vd2 T cells differ strikingly from those of human peripheral blood ab T cells. 23, 24 Notably, the majority of Vg9Vd2 T cells lack CCR7, therefore having a capacity to migrate to inflammatory lesion, including tumor local sites. 23, 24 CCR5, a receptor for CCL3, CCL4 and CCL5 is strongly expressed on gd T cells compared with ab T cells. 25 Recently, it has been reported that CCL2, CCL3 and CCL5 play an essential role not only in inflammatory diseases but also in several cancers, suggesting that gd T cells could access to the tumor local sites directly without detouring around the lymph nodes. [23] [24] [25] [26] [27] In addition, Gong et al. 28 reported that in vitro activation of Vg9Vd2 T cells by phosphoantigen and IL-2 down-regulated the IL-2-induced expansion of CD4 + CD25 + FoxP3 + regulatory T cells. It is also speculated that early IFN-g secretion through either ab or gd TCR enhances immunogenicity of tumors through mechanisms such as increased MHC expression on tumor cells, inhibit the induction of CD4 + CD25 + regulatory T cells and further promotes ab TCR recognition of target cells, 8, 29, 30 thus providing a positive feedback loop for anti-tumor immune responses. These data provide a rationale for harnessing gd T cells in adoptive T-cell transfer. 

Materials and methods
Donor samples
All healthy donors were participants with no history of autoimmune disease and selected irrespective of HLA-A*2402 expression. All samples were collected after written informed consent was obtained as part of a study approved by the Ethics Committee of Mie University Graduate School of Medicine.
T cell clone and cell lines
Clone 2-28 is a HLA-A*2402-restricted CD8 + T cell clone specific for MAGE-A4 143-151, established as described. 
Antibodies and reagents
Fluorescein isothiocyanate-conjugated anti-human TCRVg9 antibody and PE-conjugated anti-human CD8 (HIT8a) were purchased from BD Biosciences. PEconjugated anti-abTCR antibody (IP26) was purchased from eBioscience (San Diego, CA, USA). PE-conjugated MAGE-A4 143-151 /HLA-A*2402 tetramer was kindly provided by Drs P. Guilliaume and I. Luesher (The Ludwig Institute Core Facility, Lausanne, Switzerland). Antihuman CD8 (RPA-T8), anti-human CD4 (RPA-T4), antihuman HLA class I (G46-2.6) and anti-HLA class II (TU39) for blocking assays were purchased from BD Biosciences. Anti-TCR-Vg9 antibody (IMMU360) was purchased from Beckman Coulter (Krefeld, Germany). Synthetic peptides of MAGE-A4 143-151 (NYKRCFPVI) 17 and HER2 63-71 (TYLPTNASL) 31, 32 were purchased from Sawady Technology (Tokyo, Japan). Pamidronate disodium was purchased from Novartis (Nurnberg, Germany).
Generation of gd T cells
PBMCs were stimulated with 200 mM 2M3B1PP and cultured in modified Yssel's medium supplemented with 10% human albumin (Sigma, St Louis, MO, USA) in the presence of 10% AB plasma plus 100 U ml À1 recombinant human IL-2 (kindly provided by Takeda Pharmaceutical, Osaka, Japan).
Construction of TCR-containing and CD8 a/b-containing retroviral vectors RNA was isolated from clone 2-28, a HLA-A*2402-restricted CD8 + T cell clone specific for MAGE-A4 143-151 . 17 TCR a and b genes were amplified by reverse transcription-PCR and identified as TRAV8-1 and TRBV7-9, respectively. 18 The individual TCR genes were cloned into retroviral vector pMSP, 18, 33 harboring a murine stem cell virus long terminal repeat and a murine phosphoglycerate kinase promoter, to produce MS-bPa, in which murine stem cell virus long terminal repeat drives b gene and phosphoglycerate kinase promoter drives a gene. PG13 producer clones were generated and screened to produce high titer virus (Figure 2a) . RNA was isolated from PBMCs derived from a healthy donor, and CD8 a and b genes were amplified by reverse transcription-PCR. The amplified CD8 a and b genes were cloned into retroviral vector pDON-AI-2 (Takara Bio, Shiga, Japan) together with murine phosphoglycerate kinase promoter to construct pDON-AI-2-CD8 ab genes, in which Moloney murine leukemia virus long terminal repeat drives b gene and phosphoglycerate kinase promoter drives a gene. The transient retroviral vector was produced in G3T-hi cells (Takara Bio), followed by transduction of PG13 cells to generate retrovirus producer cells (Figure 2b ).
Retroviral transfer
After incubation with modified Yssel's medium for 3 days, PBMCs were transduced with MAGE-A4 143-151 -specific ab TCR and/or human CD8 ab cDNA using recombinant human fibronectin fragment CH-296 (Retronectin, Takara Bio)-coated six-well plates (Nunc, Roskilde, Denmark) and then the transduction was repeated the following day. 18 All transductions were performed at a multiplicity of infection of43.0.
Analysis and purification of MAGE-A4 143-151 /HLA-A*2402 tetramer + cells
Tetramer staining was performed as described earlier, 18, 34 and cells were analyzed by FACS Canto (BD Biosciences) or sorted on FACSAria (BD Biosciences).
Enzyme-linked immunospot assay
The number of IFN-g-secreting peptide-specific CD8 + T cells was estimated by enzyme-linked immunospot assay as described earlier. 17, 18, 20, [34] [35] [36] Briefly, flat-bottomed, 96-well, nitrocellulose-coated microtiter plates (Millipore, Bedford, MA, USA) were coated with IFN-g monoclonal antibody (1-D1K; MABTECH, Stockholm, Sweden) and effector T cells and T2-A*2402 as antigen presenting cells pulsed with 10 mM peptides were added to each well and incubated for 20-24 h. Spots were developed using biotinylated anti-IFN-g monoclonal antibody (7-B6-1-biotin; MABTECH), alkaline phosphatase conjugated streptavidin (MABTECH) and 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (Sigma) and counted with a dissecting microscope (Carl Zeiss Vision, Hallbergmoos, Germany).
Enzyme-linked immunosorbent assay
Target cells were pretreated with peptides, aminobisphosphonate or 2M3B1PP at 37 1C for 2 h, and added to sorted effector cells. The supernatant was harvested after the indicated time intervals and the concentration of IFN-g and IL-4 was measured by enzyme-linked immunosorbent assay Kit (MABTECH), according to the instructions provided by the manufacturer.
Cytotoxic assay
Cytotoxic assays were performed and the percentage of specific lysis was calculated as described earlier.
17,18
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Statistical analysis
All data were expressed as mean±s.d. Differences between groups were examined for statistical significance using the Student's t-test. A P-value o0.05 denoted the presence of a statistically significant difference.
Abbreviations
2M3B1PP, 2-Methyl-3-Butenyl-1-Pyrophosphate; CTL, Cytotoxic T lymphocytes; IFN, Interferon; IL, Interleukin; TAP, Transporter associated with antigen processing; TCR, T-cell receptor
